Corrigendum to “Cost-effective production process of scFv antibody fragments against Shiga toxin 2 via recombinant E. coli” [Curr. Res. Biotechnol. 10 (2025) 100310]
Saved in:
| Main Authors: | Marcela Guimarães, Daniela Luz, Elisabeth de Fátima Pires Augusto, Lucia Vieira, Maricilia Silva Costa, Roxane Maria Fontes Piazza, José Geraldo da Cruz Pradella |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Current Research in Biotechnology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590262825000462 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
“Stapling” scFv for multispecific biotherapeutics of superior properties
by: Lauren E. Boucher, et al.
Published: (2023-12-01) -
Novel anti-VEGF scFv antibodies with superior in vitro and in vivo activities
by: Gulcin Cakan-Akdogan, et al.
Published: (2025-07-01) -
Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo.
by: Torsten Rülker, et al.
Published: (2012-01-01) -
scFv intrabody targeting wildtype TDP-43 presents protective effects in a cellular model of TDP-43 proteinopathy
by: Yara Al Ojaimi, et al.
Published: (2025-01-01) -
Corrigendum to “Synthesis and analgesic activity of new analogs of FELL tetrapeptide containing D-Phe in the first position” [Curr. Res. Biotechnol. 8 (2024) 100249]
by: Boryana Borisova, et al.
Published: (2025-01-01)